Quick answer: Epitalon and NAD+ are both studied for cellular aging, but at different points in the pathway. Epitalon is a synthetic tetrapeptide researched mainly for telomerase activation and telomere maintenance, plus pineal/melatonin signaling. NAD+ is a coenzyme studied as fuel for sirtuins, PARP-driven DNA repair, and mitochondrial energy metabolism. Their mechanisms are non-overlapping, so they’re often researched together. Sold for research use only.
The core distinction
The simplest framing: Epitalon is studied at the level of the telomere and the “aging clock,” while NAD+ is studied at the level of cellular energy and repair machinery. One is a signaling peptide that targets telomerase; the other is a metabolic cofactor that hundreds of enzymes depend on. They address aging from different angles rather than competing.
Side-by-side
| Epitalon (Epithalon) | NAD+ | |
|---|---|---|
| What it is | Synthetic tetrapeptide (Ala-Glu-Asp-Gly), a peptide bioregulator | Nicotinamide adenine dinucleotide — an essential cellular coenzyme |
| Primary studied mechanism | Activates telomerase (hTERT); telomere maintenance; pineal/melatonin restoration | Substrate for sirtuins (SIRT1–7), PARP DNA-repair enzymes, and the mitochondrial electron transport chain |
| Main research angle | Replicative lifespan, telomere length, circadian/antioxidant signaling | Mitochondrial function, DNA repair, metabolic and energy decline with age |
| Evidence base | Largely Khavinson research group, with limited independent replication | Large, internationally replicated literature (Nature/Science/Cell) |
Mechanisms in more detail
Epitalon research centers on telomerase reverse transcriptase (hTERT) — the enzyme that maintains telomere length. In cell-culture work from Khavinson and colleagues, Epitalon induced telomerase activity in human somatic cells, lengthened telomeres, and extended replicative lifespan beyond the Hayflick limit. Additional reported effects include restoration of melatonin synthesis in the aging pineal gland and upregulation of antioxidant enzymes (SOD, catalase, glutathione peroxidase).
NAD+ is not a signaling peptide but a coenzyme required for hundreds of reactions. Tissue NAD+ levels fall substantially with age, which is studied as a driver of sirtuin deactivation, impaired PARP-mediated DNA repair, and mitochondrial dysfunction. NAD+ research therefore targets the machinery of cellular maintenance rather than the telomere directly.
Why researchers study them together
Because the two act on non-overlapping pathways — telomere maintenance (Epitalon) versus energy metabolism and DNA repair (NAD+) — they’re a logical combination in longevity-research designs, frequently paired with mitochondrial peptides such as MOTS-c. PTW offers both individually and within longevity research stacks.
Frequently asked questions
What is the main difference between Epitalon and NAD+?
Epitalon is a peptide studied for telomerase activation and telomere maintenance; NAD+ is a coenzyme studied for sirtuin activity, DNA repair, and mitochondrial energy. They target different stages of cellular aging.
Do Epitalon and NAD+ do the same thing?
No. Epitalon is researched at the level of the telomere and aging “clock,” while NAD+ is researched as fuel for repair and energy enzymes. Their non-overlapping mechanisms are why they’re studied together.
Which has the stronger evidence base?
NAD+ has a substantially larger and more internationally replicated literature. Epitalon’s evidence comes primarily from Khavinson’s research group, with limited independent replication.
Is Epitalon the same as Epithalon?
Yes — “Epitalon” and “Epithalon” are the same synthetic tetrapeptide (Ala-Glu-Asp-Gly), spelled differently across the literature.
Can they be studied together?
Yes. Their distinct mechanisms make combination research logical, often alongside mitochondrial-derived peptides in longevity stacks.
Primary-literature anchors
Cite primary sources rather than vendor pages: Khavinson et al. (Epitalon telomerase induction and telomere elongation in human somatic cells; pineal peptide bioregulation research); for NAD+, the sirtuin and NAD+-decline literature from Sinclair, Imai, and Verdin groups. Link these via PubMed.
Related research & products
For research use only. Not for human or veterinary use, diagnosis, treatment, or prevention of any condition. Not evaluated by the FDA. Author: Charles Fowler. Last updated: May 2026.